Activation of Mesocorticolimbic Dopamine Projections Initiates Cue-induced Reinstatement of Reward Seeking in Mice
Overview
Affiliations
Drug addiction is characterized by relapse when addicts are re-exposed to drug-associated environmental cues, but the neural mechanisms underlying cue-induced relapse are unclear. In the present study we investigated the role of a specific dopaminergic (DA) pathway from ventral tegmental area (VTA) to nucleus accumbens core (NAcore) in mouse cue-induced relapse. Optical intracranial self-stimulation (oICSS) was established in DAT-Cre transgenic mice. We showed that optogenetic excitation of DA neurons in the VTA or their projection terminals in NAcore, NAshell or infralimbic prefrontal cortex (PFC-IL) was rewarding. Furthermore, activation of the VTA-NAcore pathway alone was sufficient and necessary to induce reinstatement of oICSS. In cocaine self-administration model, cocaine-associated cues activated VTA DA neurons as assessed by intracellular GCaMP signals. Cue-induced reinstatement of cocaine-seeking was triggered by optogenetic stimulation of the VTA-NAcore pathway, and inhibited by chemogenetic inhibition of this pathway. Together, these results demonstrate that cue-induced reinstatement of reward seeking is in part mediated by activation of the VTA-NAcore DA pathway.
The nucleus accumbens in reward and aversion processing: insights and implications.
Xu Y, Lin Y, Yu M, Zhou K Front Behav Neurosci. 2024; 18:1420028.
PMID: 39184934 PMC: 11341389. DOI: 10.3389/fnbeh.2024.1420028.
Song R, Soler-Cedeno O, Xi Z Int J Mol Sci. 2024; 25(6).
PMID: 38542425 PMC: 10970671. DOI: 10.3390/ijms25063455.
Namba M, Xie Q, Barker J Brain Behav Immun. 2023; 113:453-475.
PMID: 37567486 PMC: 10528352. DOI: 10.1016/j.bbi.2023.07.021.
A neuropeptide signal confers ethanol state dependency during olfactory learning in .
Lindsay J, Mathies L, Davies A, Bettinger J Proc Natl Acad Sci U S A. 2022; 119(46):e2210462119.
PMID: 36343256 PMC: 9674237. DOI: 10.1073/pnas.2210462119.
Lan Q, Guan P, Huang C, Huang S, Zhou P, Zhang C Front Pharmacol. 2022; 13:872212.
PMID: 35548350 PMC: 9081529. DOI: 10.3389/fphar.2022.872212.